Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 16 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has received final approval from the USFDA for Eluxadoline Tablets, which are indicated for treating irritable bowel syndrome with diarrhea. This approval allows Zydus to manufacture the tablets at its facility in Ahmedabad and grants them eligibility for a period of shared generic drug exclusivity. The press release highlights Zydus's position as one of the first applicants to submit a complete application for these tablets. The filing serves to inform investors and the exchange about this significant regulatory approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases